Olvimulogene Nanivacirepvec

Summary

Olvimulogene Nanivacirepvec (CHEMBL4594308) is a phase-3 clinical-stage gene; indicated across 4 conditions including head and neck cancer and lung neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 4 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594308
Name	Olvimulogene Nanivacirepvec
Type	Gene
Max phase	3

Also known as: Gl-onc1, GL-ONC1, Glv-1h68, Olvimulogen nanivacirepvec, Olvimulogene nanivacirepvec, OLVIMULOGENE NANIVACIREPVEC

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
head and neck cancer	1	MONDO:0005627	EFO:0006859
lung neoplasm	1	MONDO:0021117	MONDO:0008903
neoplasm	1	MONDO:0005070	MONDO:0004992

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE1	4
PHASE3	1
PHASE1/PHASE2	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05281471	PHASE3	RECRUITING	Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician’s Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
NCT06463665	PHASE2	RECRUITING	Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
NCT01443260	PHASE1/PHASE2	COMPLETED	A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis
NCT00794131	PHASE1	COMPLETED	Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors
NCT01584284	PHASE1	COMPLETED	Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
NCT01766739	PHASE1	COMPLETED	Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
NCT02714374	PHASE1	TERMINATED	GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
NCT03420430	Not specified	NO_LONGER_AVAILABLE	Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).